KIR2DS3: A Potential Drug Target and Biomarker for Melanoma (G3808)

Target Name: KIR2DS3

NCBI ID: G3808

KIR2DS3

Other Name(s): MHC class I NK cell receptor | Killer cell immunoglobulin-like receptor 2DS3 | killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 3 | killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 3 | KI2S3_HUMAN | natural killer cell inhibitory receptor | Natural killer-associated transcript 7 | natural killer-associated transcript 7 | NKAT-7 | Natural killer cell inhibitory receptor | NKAT7 | Killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 3

KIR2DS3: A Potential Drug Target and Biomarker for Melanoma

Melanoma is a aggressive form of skin cancer that ranks fifth in the United States and has a high mortality rate due to its tendency to spread quickly and invade other organs. Despite advances in treatment, the survival rate for melanoma remains poor, with a five-year survival rate of only 9%. Therefore, there is a high need for new treatments and biomarkers to improve outcomes.

The KIR2DS3 receptor, located on the immune cell surface, is a potential drug target and biomarker for melanoma. KIR2DS3 is a non-functional RNA molecule that is expressed in many tissues, including the skin, hair, and nails. It has been shown to play a role in immune responses and has been implicated in the development and progression of several types of cancer, including melanoma.

Recent studies have suggested that KIR2DS3 may be a drug target for melanoma because of its potential role in the immune response and its expression in melanoma cells. KIR2DS3 has been shown to interact with several immune cell molecules, including T cells, NK cells, and PD-1. T cells are a crucial immune cell that play a central role in cancer immune surveillance, and NK cells are a type of immune cell that can recognize and destroy infected or mutated cells. PD-1 is a checkpoint protein that can inhibit the immune response and promote cancer growth.

One of the key advantages of targeting KIR2DS3 is its potential to disrupt the immune response and promote cancer growth. This can be done by inhibiting the activity of PD-1, which is a key regulator of the immune response. Studies have shown that inhibiting PD-1 can enhance the immune response and improve the effectiveness of cancer treatments.

Another potential mechanism by which KIR2DS3 may contribute to melanoma development is its role in cell signaling pathways. KIR2DS3 has been shown to play a role in several signaling pathways that are involved in cancer development, including the PI3K/Akt signaling pathway and the TGF-β signaling pathway. These signaling pathways are involved in cell growth, differentiation, and survival, and have been implicated in the development and progression of many types of cancer.

In addition to its potential role in cancer development, KIR2DS3 may also be a useful biomarker for melanoma. KIR2DS3 has been shown to be expressed in melanoma cells and has been used as a potential biomarker for melanoma. This suggests that KIR2DS3 could be used as a diagnostic or predictive marker for melanoma.

Furthermore, there is evidence to suggest that targeting KIR2DS3 with drugs or other therapeutic agents may have potential clinical benefits. For example, studies have shown that inhibiting KIR2DS3 with small molecules or antibodies has the potential to enhance the immune response and improve the effectiveness of cancer treatments. Additionally, inhibiting KIR2DS3 has been shown to reduce the formation of new blood vessels, which is a key factor in melanoma growth and progression.

In conclusion, KIR2DS3 is a potential drug target and biomarker for melanoma. Its role in the immune response and its expression in melanoma cells make it an attractive target for cancer therapies. Additionally, its potential as a biomarker for melanoma and its potential to disrupt signaling pathways involved in cancer development make it an important area of research. Further studies are needed to determine the full potential of KIR2DS3 as a drug target and biomarker for melanoma.

Protein Name: Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 3

Functions: Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells

The "KIR2DS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIR2DS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets